Bioventix (BVXP) investor relations material

Executive summary

• Revenue for the six months ended 31 December 2025 was £6.16 million, down from £6.73 million year-over-year.

• Profit before tax was £4.85 million, compared to £5.05 million in the prior year period.

• Tau/neuro royalties increased five-fold to £150k, reflecting growing adoption in Alzheimer's research assays.

• Core antibody sales, including vitamin D and troponin, remained steady, with mature diagnostic products supporting stable revenue.

• Interim dividend maintained at 70p per share, consistent with the previous year.

Financial highlights

• Gross profit for the period was £5.65 million, compared to £5.97 million year-over-year.

• Operating profit reached £4.78 million, down from £4.94 million in the prior year.

• Net profit for the period was £3.63 million, compared to £3.77 million year-over-year.

• Closing cash balances increased to £5.3 million from £5.1 million year-over-year.

• Basic earnings per share were 69.38p, down from 72.27p in the prior year.

Outlook and guidance

• Trading remains in line with expectations for the year ending 30 June 2026.

• Optimism for future revenue growth as IVD assays for Alzheimer's disease gain regulatory approval.

• Continued confidence in the outlook, with opportunities in neurological disease diagnostics highlighted.